With 1.12 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.56 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $7.25 whereas the lowest price it dropped to was $6.17. The 52-week range on ALMS shows that it touched its highest point at $13.53 and its lowest point at $3.18 during that stretch. It currently has a 1-year price target of $21.75.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALMS was up-trending over the past week, with a rise of 81.00%, but this was up by 59.47% over a month. Three-month performance dropped to -10.17% while six-month performance fell -35.13%. A look at the trailing 12-month EPS for ALMS yields -5.45 with Next year EPS estimates of -3.41. For the next quarter, that number is -1.54. This implies an EPS growth rate of 60.02% for this year and 17.73% for next year.
Float and Shares Shorts:
At present, 47.22 million ALMS shares are outstanding with a float of 25.25 million shares on hand for trading. On 2025-03-14, short shares totaled 3.05 million, which was 561.0 higher than short shares on 1739491200. In addition to Mr. Martin Babler Ph.D. as the firm’s President, CEO & Chairman, Dr. David M. Goldstein Ph.D. serves as its Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 0.85407996 of ALMS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, ALMS reported revenue of $0.0 and operating income of -$98622000.0. The EBITDA in the recently reported quarter was -$97802000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALMS since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALMS analysts setting a high price target of 29.0 and a low target of 15.0, the average target price over the next 12 months is 21.75. Based on these targets, ALMS could surge 300.55% to reach the target high and rise by 107.18% to reach the target low. Reaching the average price target will result in a growth of 200.41% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$5.00897 being high and -$7.67885 being low. For ALMS, this leads to a yearly average estimate of -$6.655.
